AZTherapies
AZTherapies is a privately held, Boston-based clinical-stage biotech founded in 2011 that develops proprietary therapeutics for neuroinflammation-related diseases, led by Scientific Founder/CEO David Elmaleh with Rudolph Tanzi chairing its Scientific Advisory Board.
- Company typePrivate
- Founded2011
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingBiopharmaceuticals
AZTherapies firmographics
Firmographics- Name
- AZTherapies
- Website
- https://aztherapies.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 11–50 employees
- Short description
- AZTherapies is a privately held, Boston-based clinical-stage biotech founded in 2011 that develops proprietary therapeutics for neuroinflammation-related diseases, led by Scientific Founder/CEO David Elmaleh with Rudolph Tanzi chairing its Scientific Advisory Board.
- Ownership category
- akta.pro rank
AZTherapies industry classification
Industry- NAICS
- All Other Professional, Scientific, and Technical Services (54199)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
Keywords
Where AZTherapies is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
AZTherapies business model
Business model- GTM type
- B2B
- Offering type
- Biopharmaceuticals
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
AZTherapies product offering
Product offeringCore offering
AZTherapies is a clinical-stage biotechnology company developing breakthrough therapeutic treatments for neuroinflammation-related diseases. The company advances a pipeline of drug candidates targeting central nervous system (CNS) conditions, with research and clinical operations focused on translating neuroinflammation science into disease-modifying therapies.
Differentiator
Problem solved
Functional benefit
Companies that use AZTherapies
Customer profileIdeal customer profiles1 record
AZTherapies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AZTherapies competitors and assessment
Company assessmentBroad incumbents
- Eisai: Co-developer of Leqembi (lecanemab) with Biogen for early Alzheimer's. Direct competitor establishing the amyloid-targeting paradigm that AZTherapies' neuroinflammation approach must differentiate against.
- Biogen: Large-cap neuroscience company with approved Alzheimer's antibodies (Aduhelm, Leqembi). Direct competitor in the AD treatment space, with substantially greater resources and commercial reach.
- Eli Lilly: Major pharma with Kisunla (donanemab), an FDA-approved anti-amyloid antibody for Alzheimer's. Competes in the same disease via a different mechanism, setting the standard of care.
Direct peers
- Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Comparably sized, late-clinical-stage peer in the AD space pursuing a non-amyloid mechanism of action.
- Anavex Life Sciences: Clinical-stage biotech developing ANAVEX compounds (e.g., blarcamesine) for Alzheimer's, Rett syndrome and other neurodegenerative indications. Comparably sized peer in CNS drug development.
- Prothena: Clinical-stage biotech with a pipeline of protein immunotherapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable in stage, modality and disease focus.
- Denali Therapeutics: Clinical-stage biotech with a neurodegeneration and neuroinflammation pipeline (e.g., DNL151, TREM2 programs). Compares on disease focus and stage, with broader CNS pipeline diversification.
- INmune Bio: Clinical-stage biotech developing XPro1595, a TNF inhibitor targeting neuroinflammation in Alzheimer's and other CNS diseases. Most direct mechanistic peer to AZTherapies' neuroinflammation thesis.
- Alector: Clinical-stage biotech developing immuno-neurology therapies (AL001, AL002) for neurodegenerative diseases including frontotemporal dementia and Alzheimer's. Closely comparable in modality and disease focus.
Emerging players
- Cortexyme (now Spyre Therapeutics): Was developing atuzaginstat for Alzheimer's targeting a P. gingivalis neuroinflammation mechanism before corporate restructuring. Historical direct peer in neuroinflammation-modulated AD therapeutics.
Market position
Customer concentration
AZTherapies social profiles
Digital presenceAZTherapies financial estimates
Financial estimateRevenue estimate
Valuation estimate
AZTherapies leadership team
Management profileNumber of profiles
Profiles14 records
AZTherapies funding detail
Funding detailFunding overview
Funding rounds8 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AZTherapies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AZTherapies
What does AZTherapies do?
AZTherapies is a clinical-stage biotechnology company developing breakthrough therapeutic treatments for neuroinflammation-related diseases. The company advances a pipeline of drug candidates targeting central nervous system (CNS) conditions, with research and clinical operations focused on translating neuroinflammation science into disease-modifying therapies.
When was AZTherapies founded?
AZTherapies was founded in 2011. It employs 11 to 50 people.
Where is AZTherapies based?
AZTherapies is headquartered in Boston, United States, in the North America region.
Who are AZTherapies's main competitors?
Broad incumbents on record are Eisai, Biogen and Eli Lilly. Direct peers are Cassava Sciences, Anavex Life Sciences, Prothena, Denali Therapeutics, INmune Bio and Alector. Cortexyme (now Spyre Therapeutics) is listed as an emerging player.
Does AZTherapies have an API?
No public API is recorded for AZTherapies.
What industry is AZTherapies in?
Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 54199 and its SIC code is 8731.